MDS vs AML Classification Review in Genomic-Era Hematology

Distinguishing myelodysplastic syndromes (MDS) from acute myeloid leukemia (AML) increasingly requires multi-factor reasoning across blast percentages, genomic findings, cytogenetics, and treatment context.

Haem.io is designed to execute this criteria logic consistently while preserving traceability to specific rules in WHO 2022 and ICC 2022 frameworks.

Why this matters

• Borderline presentations can affect downstream clinical review and risk framing.
• Guideline complexity has grown beyond practical manual execution at scale.
• Auditable, deterministic tooling helps reduce inconsistency and drift.